Clin Colon Rectal Surg 2020; 33(05): 253-257
DOI: 10.1055/s-0040-1713742
Review Article

Expanding Uses of HIPEC for Locally Advanced Colorectal Cancer: A European Perspective

Delia Cortes-Guiral
1   General Surgery Department, Principe de Asturias University Hospital, Carretera de Alcala s/n, Alcalá de Henares, Madrid, Spain
,
Olivier Glehen
2   General Surgery Department (Surgical Oncology), Centre Hospitalier Lyon Sud (Hospices Civils de Lyon), Lyon, France
› Author Affiliations

Abstract

Locally advanced colorectal cancer is a challenge for surgeons and medical oncologist; 10 to 20% colorectal cancer debut as locally advanced disease, with tumors extending through the colon wall with perforation and/or invasion of adjacent organs or structures. Those locally advanced tumors have a worse prognostic at any stage due not only to systemic dissemination but also in a high percentage of patients, to locoregional recurrence, in fact, peritoneal carcinomatosis of colorectal origin is so predictable that we can assess the risk for each patient according to some histopathological and clinical features: small peritoneal nodules resected in the first surgery (70% probability), ovarian metastases (60%), perforated tumor onset or intraoperative tumor rupture (50%), positive cytology (40%), and pT4/mucinous pT3 up to 40%. Prophylactic or adjuvant hyperthermic intraperitoneal chemotherapy seems to be a promising strategy for patients with advanced colorectal cancer to prevent the development of peritoneal recurrence and improve prognosis of this group of patients.



Publication History

Article published online:
18 September 2020

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 
  • References

  • 1 Russell AH, Tong D, Dawson LE, Wisbeck W. Adenocarcinoma of the proximal colon. Sites of initial dissemination and patterns of recurrence following surgery alone. Cancer 1984; 53 (02) 360-367
  • 2 Landmann RG, Weiser MR. Surgical management of locally advanced and locally recurrent colon cancer. Clin Colon Rectal Surg 2005; 18 (03) 182-189
  • 3 Taylor WE, Donohue JH, Gunderson LL. , et al. The Mayo Clinic experience with multimodality treatment of locally advanced or recurrent colon cancer. Ann Surg Oncol 2002; 9 (02) 177-185
  • 4 Curley SA, Carlson GW, Shumate CR, Wishnow KI, Ames FC. Extended resection for locally advanced colorectal carcinoma. Am J Surg 1992; 163 (06) 553-559
  • 5 Honoré C, Goéré D, Souadka A, Dumont F, Elias D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol 2013; 20 (01) 183-192
  • 6 Trilling B, Cotte E, Vaudoyer D. , et al. Intraperitoneal-free cancer cells represent a major prognostic factor in colorectal peritoneal carcinomatosis. Dis Colon Rectum 2016; 59 (07) 615-622
  • 7 Kyang LS, Valle SJ, Alzahrani NA, Morris DL. Prevention of peritoneal recurrence in high-risk colorectal cancer and evidence of T4 status as a potential risk factor. ANZ Journal of Surgery 2018; 88 (10) 975-981
  • 8 Sugarbaker PH. Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. World J Gastroenterol 2014; 20 (28) 9286-9291
  • 9 Segelman J, Akre O, Gustafsson UO, Bottai M, Martling A. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. Colorectal Dis 2014; 16 (05) 359-367
  • 10 Segelman J, Akre O, Gustafsson UO, Bottai M, Martling A. External validation of models predicting the individual risk of metachronous peritoneal carcinomatosis from colon and rectal cancer. Colorectal Dis 2016; 18 (04) 378-385
  • 11 Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012; 13 (11) 1152-1160
  • 12 Mokhles S, Macbeth F, Farewell V. , et al. Meta-analysis of colorectal cancer follow-up after potentially curative resection. Br J Surg 2016; 103 (10) 1259-1268
  • 13 Ocaña A, Díez-González L, García-Olmo DC. , et al. Circulating DNA and survival in solid tumors. Cancer Epidemiol Biomarkers Prev 2016; 25 (02) 399-406
  • 14 Olmedillas López S, García-Olmo DC, García-Arranz M, Guadalajara H, Pastor C, García-Olmo D. KRAS G12V mutation detection by droplet digital PCR in circulating cell-free DNA of colorectal cancer patients. Int J Mol Sci 2016; 17 (04) 484
  • 15 Elias D, Lefevre JH, Chevalier J. , et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27 (05) 681-685
  • 16 Goéré D, Malka D, Tzanis D. , et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?. Ann Surg 2013; 257 (06) 1065-1071
  • 17 Klaver CE, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ. ; research committee of the European Society of Coloproctology. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis 2017; 19 (03) 224-236
  • 18 Glehen O, Gilly FN, Boutitie F. , et al; French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010; 116 (24) 5608-5618
  • 19 Passot G, Vaudoyer D, Cotte E. , et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg 2012; 256 (01) 125-129
  • 20 Dromain C, Leboulleux S, Auperin A. , et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging 2008; 33 (01) 87-93
  • 21 Sugarbaker PH. Second-look surgery for colorectal cancer: revised selection factors and new treatment options for greater success. Int J Surg Oncol 2011; 2011
  • 22 Elias D, Honoré C, Dumont F. , et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2011; 254 (02) 289-293
  • 23 del Moral Ángel Serrano. Second-look surgery plus HIPEC for patients at high-risk of peritoneal recurrence after colorectal surgery, without evidence of relapse. Cirugía Española 2018; 96 (02) 96-101
  • 24 Sammartino P, Sibio S, Biacchi D. , et al. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Colorectal Dis 2014; 29 (09) 1081-1089
  • 25 Tentes AA, Kakolyris S, Pallas N. , et al. Preliminary results with the use of hyperthermic intraperitoneal intraoperative chemotherapy or systemic chemotherapy in high-risk colorectal cancer patients. Transl Gastrointest Cancer 2013; 2 (01) 6-10
  • 26 Ripley RT, Davis JL, Kemp CD, Steinberg SM, Toomey MA, Avital I. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. Trials 2010; 11 (01) 62
  • 27 Klaver CE, Musters GD, Bemelman WA. , et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer 2015; 15: 428
  • 28 Arjona-Sánchez A, Barrios P, Boldo-Roda E. , et al. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer 2018; 18 (01) 183
  • 29 Arjona-Sanchez A. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (HIPEC) by minimally invasive approach, an initial experience. World J Surgery 2018; 42 (10) 3120-3124
  • 30 Valle SJ, Alzahrani NA, Alzahrani SE, Liauw W, Morris DL. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. Int J Surg 2015; 23 (Pt A): 176-180